AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the formula (I):



(I)

wherein R^7 and R^{21} are the same or are different and represent

-O-benzoyl,

OH, or

RC(=Y)-O-, wherein Y represents an oxygen atom, and R represents

piperazinyl, alkyl, -O-phenyl, -N-alkyl or -NH-phenyl,

~~a C_6 to C_{14} aryl group which may have a substituent, or~~

~~a C_6 to C_{14} aryloxy group which may have a substituent, or~~

~~$R^{N1}R^{N2}N$-R^M, wherein R^M represents~~

~~a) a single bond,~~

~~b) -CO-O-,~~

~~c) -CS-O- or~~

~~d) -CO-NR^{N3}-, wherein R^{N3} represents a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom, and~~

~~wherein R^{N1} and R^{N2} are the same or are different and represent~~

~~a) a hydrogen atom,~~

~~b) a C_1 to C_{22} alkyl group which may have a substituent,~~

~~c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,~~

~~d) an aliphatic C_2 to C_{22} acyl group which may have a substituent,~~

~~e) an aromatic C_7 to C_{15} acyl group which may have a substituent,~~

~~f) a C_6 to C_{14} aryl group which may have a substituent,~~

~~g) a 5-membered to 14-membered heteroaryl group which may have a substituent,~~

~~h) a C_7 to C_{22} aralkyl group which may have a substituent,~~

~~i) a C_1 to C_{22} alkylsulfonyl group which may have a substituent,~~

~~j) a C_6 to C_{14} arylsulfonyl group which may have a substituent,~~

~~k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,~~

~~l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,~~

~~m) a C_3 to C_{14} cycloalkyl group which may have a substituent or~~

~~n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent;~~ or

a pharmacologically acceptable salt ~~thereof,~~ thereof.

~~wherein said substituents are each independently selected from the group consisting of: C_1-C_6 alkyl group, phenyl group, halogen, hydroxyl group, C_1-C_6 alkoxy group, thiol group, C_1-~~

~~C_6 alkylthio group, nitro group, nitroso group, cyano group, C_1-C_6 alkoxycarbonyl group, amino group, mono (C_1-C_6 alkyl) amino group, di (C_1-C_6 alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.~~

2. (Currently Amended) The compound according to claim 1 represented by the formula (I-a):



(I -a)

wherein R^{7a} and R^{21a} are the same or are different and represent

$R^aC(=Y^a)$-O-, wherein Y^a represents an oxygen atom, and R^a represents

~~a C_6 to C_{14} aryl group which may have a substituent, or~~

~~a C_6 to C_{14} aryloxy group which may have a substituent, or~~

~~$R^{aN1}R^{aN2}$N-CO-O-, wherein R^{aN1} and R^{aN2}, the same or different, represent~~

~~a) a hydrogen atom,~~

[[b)]] a C_1 to C_{22} alkyl group ~~which may have a substituent,~~

[[c)]] an unsaturated C_2 to C_{22} alkyl group ~~which may have a substituent,~~

~~d) a C_6 to C_{14} aryl group which may have a substituent,~~

~~e) a 5-membered to 14-membered heteroaryl group which may have a substituent,~~

~~f) a C_7 to C_{22} aralkyl group which may have a substituent,~~

~~g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN1} and R^{aN2} together in combination with the nitrogen atom to which R^{aN1} and R^{aN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,~~

~~h) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,~~

[[i)]] a C_3 to C_{14} cycloalkyl group ~~which may have a substituent or~~

~~j) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, or~~

~~$R^{aN1}R^{aN2}N$-CS-O-, wherein R^{aN1} and R^{aN2} are the same as defined above,~~

[[;]] or a pharmacologically acceptable salt ~~thereof~~, thereof.

~~wherein said substituents are each independently selected from the group consisting of: C_1-C_6 alkyl group, phenyl group, halogen, hydroxyl group, C_1-C_6 alkoxy group, thiol group, C_1-C_6 alkylthio group, nitro group, nitroso group, cyano group, C_1-C_6 alkoxycarbonyl group, amino group, mono (C_1-C_6 alkyl) amino group, di (C_1-C_6 alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.~~

3. (Canceled).

4. (Currently Amended) The compound according to claim 1, wherein R^7 and R^{21} R^{N1} ~~and R^{N2}~~ are the same or are different and represent a C_1 to C_6 alkyl group ~~or C_6 to C_{14} aryl group,~~

or ~~form, together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, a non-aromatic heterocyclic group selected from the group consisting of:~~



or a pharmacologically acceptable salt thereof.

5-18. (Canceled).

19. (Currently Amended) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide, (8E,12E,14E)-21-(N,N-dimethylcarbamoyloxy)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide, ~~(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide~~ and (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-phenylcarbamoyloxy-18,19-epoxytricosa-8,12,14-trien-11-olide; or a

pharmacologically acceptable salt thereof.

20. (Canceled).

21. (Previously Presented) A pharmaceutical composition comprising the compound according to claim 1, or a pharmacologically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

22-45. (Canceled).